The safety and immunogenicity of inactivated rotavirus vaccine delivered by a dissolving microneedle patch in rats

ABSTRACT The development of dissolving microneedle patches (dMNPs) for inactivated rotavirus vaccine (IRV) requires concurrent evaluation of safety parameters, including local and systemic toxicity and immune response characteristics. The aim of this study is to evaluate the toxicological safety profiles and immunogenic potential of IRV dMNPs in rats through assessment of systemic toxicity, local responses, and neutralizing activities. IRV dMNPs were examined for stability under different storage conditions (5 ± 3°C and 25 ± 2°C) for up to 24 months. Toxicology assessment included clinical observation, body weight monitoring, food consumption, hematology, clinical chemistry, organ weight analysis, and histopathological examination. Local tolerance was evaluated using Draize scoring and microscopic examination of the administration sites. Immunogenicity was evaluated by measuring neutralizing activities in sera against homotypic and heterotypic RV strains. The potency of IRV dMNPs was found stable for at least 24 months at 5 ± 3°C, and for 12 months at 25 ± 2°C. Toxicological evaluation showed no adverse systemic effects, with all clinical pathology parameters remaining within normal ranges. Local dermal reactions were mild (mean Draize scores <1.5) and subsided within 48 h. Histopathology showed only low to mild inflammatory changes at the application sites, with complete resolution by the end of study (day 57). Immunological analysis showed robust and cross-reactive neutralizing activities against homotypic and heterotypic RV strains in sera of rats. IRV dMNPs showed strong stability and an excellent safety profile while also inducing robust and extensive immune responses, supporting its further development as an alternate IRV platform.

• Publication year

  2025

• Venue

  Human Vaccines & Immunotherapeutics

• Publication date

  2025-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/21645515.2025.2555700PMID 40936299PMCID 12439544
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development and validation of a VP7-specific EIA for determining the potency and stability of inactivated rotavirus vaccine.

  2024cited by this paper
• A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial

  2024cited by this paper
• Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques

  2023cited by this paper
• Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine

  2022cited by this paper
• Interventions to improve oral vaccine performance: a systematic review and meta-analysis

  2019cited by this paper
• Dilemmas With Rotavirus Vaccine: The Neonate and Immunocompromised.

  2019cited by this paper
• Development of a thermostable microneedle patch for polio vaccination

  2018cited by this paper
• Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice

  2018cited by this paper
• The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.

  2017cited by this paper
• Intussusception Rates Before and After the Introduction of Rotavirus Vaccine

  2016cited by this paper
• Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets

  2016cited by this paper
• Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.

  2016cited by this paper
• Inactivated human rotavirus vaccine induces heterotypic antibody response: Correction and development of IgG avidity assay

  2015cited by this paper
• Measles vaccination using a microneedle patch.

  2013cited by this paper
• Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity?

  2013influential reference
• Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch.

  2013cited by this paper
• Microneedles for drug and vaccine delivery.

  2012cited by this paper
• Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations

  2011cited by this paper
• Dissolving Polymer Microneedle Patches for Influenza Vaccination

  2010cited by this paper
• Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets.

  2010cited by this paper
• Performance of rotavirus vaccines in developed and developing countries

  2010cited by this paper
• Antigen delivery via two molecules on the CD8– dendritic cell subset induces humoral immunity in the absence of conventional “danger”

  2005cited by this paper
• Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.

  1999cited by this paper

• No citing papers are available for this paper.